

Chantale Bernatchez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/443309/publications.pdf>

Version: 2024-02-01

94
papers

9,487
citations

61984

43
h-index

53230

85
g-index

96
all docs

96
docs citations

96
times ranked

15663
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. <i>Lung Cancer</i> , 2022, 164, 69-75.	2.0	2
2	Isolation and Maintenance of Tumor-Infiltrating Lymphocytes for Translational and Clinical Applications: Established Methods and New Developments. <i>Methods in Molecular Biology</i> , 2022, 2435, 43-71.	0.9	0
3	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
4	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
5	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	12.8	9
6	Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. <i>Cancer Discovery</i> , 2022, 12, 2330-2349.	9.4	22
7	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 127-139.	1.1	48
8	Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1101-1113.	4.2	18
9	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	30.7	357
10	Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. <i>Nature Genetics</i> , 2021, 53, 332-341.	21.4	112
11	Identification of bacteria-derived HLA-bound peptides in melanoma. <i>Nature</i> , 2021, 592, 138-143.	27.8	187
12	Tilsofolimod with Ipilimumab Drives Tumor Responses in Anti-“PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	9.4	32
13	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	7.0	28
14	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. <i>Scientific Reports</i> , 2021, 11, 8511.	3.3	24
15	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
16	Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. <i>Journal of Surgical Oncology</i> , 2021, 124, 699-703.	1.7	2
17	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
18	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. <i>Blood Advances</i> , 2021, 5, 2519-2522.	5.2	10

#	ARTICLE	IF	CITATIONS
19	Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531.		24
20	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Reports, 2021, 36, 109410.	6.4	17
21	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clinical Cancer Research, 2021, 27, 5062-5071.	7.0	8
22	Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Clinical Cancer Research, 2021, 27, 5912-5921.	7.0	57
23	Deep learning-based prediction of the T cell receptor’s antigen binding specificity. Nature Machine Intelligence, 2021, 3, 864-875.	16.0	99
24	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	7.0	13
25	Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
26	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
27	Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunology Research, 2020, 8, 794-805.	3.4	17
28	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer, 2020, 146, 303-309.	2.0	2
29	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nature Communications, 2020, 11, 660.	12.8	68
30	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nature Communications, 2020, 11, 661.	12.8	124
31	Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. Cancers, 2020, 12, 255.	3.7	58
32	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
33	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	12.8	15
34	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
35	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discovery, 2020, 10, 1158-1173.	9.4	158
36	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1747-1757.	4.2	16

#	ARTICLE	IF	CITATIONS
37	Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. <i>European Journal of Immunology</i> , 2019, 49, 2245-2251.	2.9	4
38	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. <i>Cancers</i> , 2019, 11, 714.	3.7	79
39	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R β -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721.	9.4	180
40	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1692-1697.	7.1	237
41	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus-Related Cancer. <i>JAMA Oncology</i> , 2019, 5, 67.	7.1	344
42	Baseline tumor-immune signatures associated with response to bempedaldesleukin (NKTR-214) and nivolumab. <i>Journal of Clinical Oncology</i> , 2019, 37, 2623-2623.	1.6	20
43	TIL therapy and anti-CTLA4: can they co-exist?. <i>Oncotarget</i> , 2019, 10, 1-2.	1.8	1
44	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
45	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , 2018, 27, 977-987.e4.	16.2	398
46	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283.	4.5	45
47	T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 2920-2934.	7.0	58
48	Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-8.	3.0	13
49	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , 2018, 9, 3919.	12.8	120
50	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	28.9	892
51	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. <i>Cancer Discovery</i> , 2018, 8, 1366-1375.	9.4	80
52	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
53	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2018, 41, 399-405.	2.4	32
54	Resident Breast T Cells: The Troops Are Already There. <i>Trends in Molecular Medicine</i> , 2018, 24, 821-822.	6.7	1

#	ARTICLE	IF	CITATIONS
55	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
56	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunology Research, 2017, 5, 100-105.	3.4	46
57	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research, 2017, 5, 300-311.	3.4	20
58	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research, 2017, 5, 319-329.	3.4	25
59	4-1BB Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. Cancer Immunology Research, 2017, 5, 439-445.	3.4	45
60	SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunology Research, 2017, 5, 618-629.	3.4	34
61	OA20.06 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer - The ICON Project. Journal of Thoracic Oncology, 2017, 12, S324-S325.	1.1	3
62	P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S630-S631.	1.1	1
63	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	3.8	120
64	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 7263-7275.	7.0	41
65	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Scientific Reports, 2017, 7, 13380.	3.3	208
66	Absence of Grail promotes CD8+ T cell anti-tumour activity. Nature Communications, 2017, 8, 239.	12.8	22
67	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	9.4	160
68	Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clinical Cancer Research, 2017, 23, 6151-6164.	7.0	58
69	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. OncoImmunology, 2017, 6, e1321187.	4.6	45
70	A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. Frontiers in Immunology, 2017, 8, 908.	4.8	50
71	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. Journal of Hematology and Oncology, 2016, 9, 81.	17.0	62
72	A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50

#	ARTICLE	IF	CITATIONS
73	Loss of IFN- β Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. <i>Cell</i> , 2016, 167, 397-404.e9.	28.9	1,009
74	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	5.5	106
75	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
76	The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. <i>Oncolmunology</i> , 2016, 5, e1057386.	4.6	22
77	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0160004.	2.5	33
78	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 602-609.	3.4	133
79	BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. <i>Oncolmunology</i> , 2015, 4, e1014246.	4.6	50
80	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. <i>Cancer Immunology Research</i> , 2015, 3, 1201-1206.	3.4	29
81	Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 448-460.	2.4	47
82	Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 160-175.	2.0	176
83	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 5329-5340.	7.0	266
84	PD-1 and BTLA and CD8 ⁺ T-cell "exhaustion" in cancer. <i>Oncolmunology</i> , 2012, 1, 735-738.	4.6	71
85	Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. <i>Journal of Immunology</i> , 2012, 189, 5476-5484.	0.8	37
86	A New Approach to Simultaneously Quantify Both TCR α - and β -Chain Diversity after Adoptive Immunotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 4733-4742.	7.0	21
87	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770.	7.0	345
88	Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy. <i>Seminars in Oncology</i> , 2012, 39, 215-226.	2.2	34
89	Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. <i>Vaccine</i> , 2011, 29, 3021-3030.	3.8	12
90	New epitopes to improve peptide vaccination against the tumor-associated antigen Survivin. <i>FASEB Journal</i> , 2008, 22, 526-526.	0.5	0

#	ARTICLE	IF	CITATIONS
91	Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans. <i>FASEB Journal</i> , 2003, 17, 1068-1080.	0.5	51
92	Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. <i>Blood</i> , 2003, 102, 2901-2909.	1.4	98
93	Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. <i>Carcinogenesis</i> , 1999, 20, 757-763.	2.8	87
94	Residues involved in co-factor and substrate binding of the short-chain dehydrogenase/reductase PTR1 producing methotrexate resistance in <i>Leishmania</i> . <i>FEBS Journal</i> , 1998, 251, 768-774.	0.2	18